|
|
Article: Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune Allergy Treatment.
- Article from:
- Clinical Trials Week
- Article date:
- January 19, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Circassia Ltd, a specialty biopharmaceutical company focused on
allergy and critical care, announced that following successful clinical results achieved in 2008 with its ToleroMune(R) anti-allergy technology, the company has now completed patient recruitment for a further phase II clinical trial in cat allergy. The study, which is underway in Canada, has recruited 120 patients with confirmed cat allergies, and all the participants have completed screening and initial dosing with none experiencing any significant adverse events or safety issues. Circassia anticipates completing patient dosing in the next three months, with follow-up post-treatment challenge visits ...
Related newspaper, magazine, and journal articles:
|
|
Article: Studies from A.P. Jonville-Bera et al in the area of ...
Biotech Week;
July 8, 2009 ;
700+ words
... ... Auckland 10, New Zealand. Keywords: France, Tours, Adverse Drug Reactions, Adverse Drug Effect, Adverse Drug Event, Adverse Drug Reaction, Clinical Trial Research, Drug Development, Drug Safety, Therapy, Treatment. This article was ...
|
|